Immunovant, Inc. (IMVT)
37.02
+0.37
(+1.01%)
USD |
NASDAQ |
Sep 16, 13:25
Immunovant Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.0001 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.0001 |
| December 31, 2024 | 0.0001 |
| September 30, 2024 | 0.0001 |
| June 30, 2024 | 0.0001 |
| March 31, 2024 | 0.0002 |
| December 31, 2023 | 0.0005 |
| September 30, 2023 | 0.0024 |
| June 30, 2023 | 0.0031 |
| March 31, 2023 | 0.0043 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.0036 |
| September 30, 2022 | 0.0045 |
| June 30, 2022 | 0.0048 |
| March 31, 2022 | 0.0054 |
| December 31, 2021 | 0.0055 |
| September 30, 2021 | 0.0057 |
| June 30, 2021 | 0.0084 |
| March 31, 2021 | 0.0087 |
| December 31, 2020 | 0.0084 |
| September 30, 2020 | 0.0089 |
| June 30, 2020 | 0.0152 |
| March 31, 2020 | 0.0339 |
| December 31, 2019 | 0.0262 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Moderna, Inc. | 0.1904 |
| Altimmune, Inc. | 0.076 |
| TG Therapeutics, Inc. | 1.249 |
| Dianthus Therapeutics, Inc. | 0.0011 |
| First Tracks Biotherapeutics, Inc. | 0.0257 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 852.49M |
| Total Liabilities (Quarterly) | 117.10M |
| Shareholders Equity (Quarterly) | 735.39M |
| Current Ratio | 7.269 |
| Net Debt Paydown Yield | 0.00% |